GlassScriptPhysician profile
Kevin C Strait
NPI 1467465179
$2,183.75
in general payments reported to CMS, 2019-2025
23 companies · $57.48 in 2025
The $57.48 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $465 · 2025: $57.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.04 | 2019-2020 | |
| Amgen INC. | $221.27 | 2019-2020 | |
| Pfizer INC. | $202.92 | 2019-2020 | |
| Amarin Pharma, INC. | $201.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $168.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $152.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $148.14 | 2019-2020 | |
| Novo Nordisk INC | $125.02 | 2019-2020 | |
| Lilly USA, LLC | $109.45 | 2019 | |
| Merck Sharp & Dohme LLC | $101.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.42 | 2019-2020 | |
| Grifols USA, LLC | $73.07 | 2019-2020 | |
| Astellas Pharma US INC | $69.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.77 | 2019-2020 | |
| Circassia INC. | $25.79 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.39 | 2019 | |
| Insulet Corporation | $17.78 | 2019 | |
| Daiichi Sankyo INC. | $15.63 | 2019 | |
| Advanced Respiratory, INC | $15.09 | 2019 | |
| Abbott Laboratories | $15.08 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Strait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.